RU2015146418A - Библиотека синтетических специфически связывающих молекул - Google Patents
Библиотека синтетических специфически связывающих молекул Download PDFInfo
- Publication number
- RU2015146418A RU2015146418A RU2015146418A RU2015146418A RU2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- specific antigen
- binding molecule
- seq
- dna sequences
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims 80
- 102000036639 antigens Human genes 0.000 claims 80
- 108091007433 antigens Proteins 0.000 claims 80
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 238000000034 method Methods 0.000 claims 11
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 5
- 230000003321 amplification Effects 0.000 claims 4
- 238000010367 cloning Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 238000002955 isolation Methods 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000009466 transformation Effects 0.000 claims 4
- 241000251729 Elasmobranchii Species 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000012491 analyte Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 241000023308 Acca Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361815043P | 2013-04-23 | 2013-04-23 | |
| US61/815,043 | 2013-04-23 | ||
| PCT/EP2014/058251 WO2014173959A2 (en) | 2013-04-23 | 2014-04-23 | Synthetic library of specific binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015146418A true RU2015146418A (ru) | 2017-05-26 |
| RU2015146418A3 RU2015146418A3 (enExample) | 2018-05-07 |
Family
ID=50543598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015146418A RU2015146418A (ru) | 2013-04-23 | 2014-04-23 | Библиотека синтетических специфически связывающих молекул |
| RU2015146419A RU2015146419A (ru) | 2013-04-23 | 2014-04-23 | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015146419A RU2015146419A (ru) | 2013-04-23 | 2014-04-23 | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10472410B2 (enExample) |
| EP (3) | EP2989203B1 (enExample) |
| JP (2) | JP6591964B2 (enExample) |
| KR (2) | KR20160010466A (enExample) |
| CN (2) | CN105492610B (enExample) |
| AU (3) | AU2014257549B2 (enExample) |
| BR (2) | BR112015026729A2 (enExample) |
| CA (2) | CA2909921C (enExample) |
| DK (1) | DK2989203T3 (enExample) |
| RU (2) | RU2015146418A (enExample) |
| WO (2) | WO2014173959A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4151658A1 (en) | 2012-05-07 | 2023-03-22 | Elasmogen Limited | Single domain binding molecule |
| US10472410B2 (en) | 2013-04-23 | 2019-11-12 | The University Court Of The University Of Aberdeen | Isolation of therapeutic target specific VNAR domains to ICOSL |
| CA2953569A1 (en) | 2014-06-26 | 2015-12-30 | Ossianix, Inc. | Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds |
| CN107074961A (zh) * | 2014-11-03 | 2017-08-18 | 默克专利股份公司 | 用于生成双特异性鲨鱼可变抗体结构域的方法及其用途 |
| CA2967830A1 (en) | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | Tfr selective binding compounds and related methods |
| ITUB20151014A1 (it) * | 2015-05-27 | 2016-11-27 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi |
| KR20250095754A (ko) | 2016-04-15 | 2025-06-26 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 |
| CN107130300A (zh) * | 2016-10-08 | 2017-09-05 | 深圳劲宇生物科技有限公司 | 一种dna编码分子库的合成方法及dna模板 |
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR102657978B1 (ko) | 2017-09-27 | 2024-04-16 | 엘라스모겐 리미티드 | 특이적 결합 분자 |
| US11180544B2 (en) * | 2017-11-07 | 2021-11-23 | City University Of Hong Kong | Method of producing antibody fragment |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2020056327A1 (en) | 2018-09-14 | 2020-03-19 | Ossianix, Inc. | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers |
| CN111197074B (zh) * | 2018-11-20 | 2023-08-15 | 深圳华大生命科学研究院 | 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用 |
| WO2020167872A1 (en) * | 2019-02-11 | 2020-08-20 | Woodbury Neal W | Systems, methods, and media for molecule design using machine learning mechanisms |
| GB201906997D0 (en) * | 2019-05-17 | 2019-07-03 | Elasmogen Ltd | Conjugates |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| JP7765090B2 (ja) * | 2020-05-01 | 2025-11-06 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | ナノボディ及びナノボディ親和性を同定するための組成物及び方法 |
| CN112301431B (zh) * | 2020-08-12 | 2023-01-31 | 华东理工大学 | 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法 |
| GB202020154D0 (en) * | 2020-12-18 | 2021-02-03 | Almac Discovery Ltd | ROR1-specific variant antigen binding molecules |
| GB202020152D0 (en) | 2020-12-18 | 2021-02-03 | Elasmogen Ltd | Fast-track humanisation of specific binding molecules |
| WO2022212429A1 (en) * | 2021-03-31 | 2022-10-06 | Sachdev Sidhu | Anti-viral compositions for rift valley fever virus infections and methods of using same |
| EP4141028A1 (en) | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
| GB202407865D0 (en) | 2024-06-03 | 2024-07-17 | Elasmogen Ltd | Self immolative compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008419D0 (en) * | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| PT1419179E (pt) | 2001-08-10 | 2010-03-16 | Univ Aberdeen | Domínios de ligação de antigenes |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| ES2458636T3 (es) * | 2003-08-18 | 2014-05-06 | Medimmune, Llc | Humanización de anticuerpos |
| EP2261332A3 (en) * | 2003-08-27 | 2012-05-09 | Proterec Ltd | Libraries of recombinant chimeric proteins |
| EP1751181B1 (en) | 2004-06-02 | 2012-08-15 | AdAlta Pty Ltd | BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS |
| US7728114B2 (en) * | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| WO2006003999A1 (ja) | 2004-07-05 | 2006-01-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント |
| AU2006227377B2 (en) | 2005-03-18 | 2013-01-31 | Medimmune, Llc | Framework-shuffling of antibodies |
| EP2368993A3 (en) | 2005-03-25 | 2012-06-13 | National Research Council Of Canada | Method for isolation of soluble polypeptides |
| EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
| EA021669B1 (ru) | 2005-07-18 | 2015-08-31 | Амджен Инк. | Нейтрализующие антитела человека против b7rp1 |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101528767A (zh) | 2006-10-11 | 2009-09-09 | 埃博灵克斯股份有限公司 | 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途 |
| WO2009026638A1 (en) | 2007-08-31 | 2009-03-05 | Melbourne Health | Marine-animal derived therapeutic and diagnostic agents for hepatitis b |
| EP2344545A4 (en) * | 2008-10-06 | 2012-10-03 | Commw Scient Ind Res Org | CRYSTALLINE STRUCTURE OF BETA-AMYLOID PEPTIDE |
| CA2738801A1 (en) * | 2008-10-07 | 2010-04-15 | Zap Holdings Limited | Synchronization of relational databases with olap cubes |
| US8496933B2 (en) | 2009-11-04 | 2013-07-30 | Laboratorios Silanes, S.A. De C.V. | VHNAR anti-cytokine domains |
| US20140154241A1 (en) * | 2010-12-03 | 2014-06-05 | Cyclogenix Ltd | Binding peptides i |
| EP4151658A1 (en) | 2012-05-07 | 2023-03-22 | Elasmogen Limited | Single domain binding molecule |
| CN103031304A (zh) * | 2012-12-27 | 2013-04-10 | 苏州大学 | 一种微小rna用于调控b7-h2基因表达 |
| US10472410B2 (en) | 2013-04-23 | 2019-11-12 | The University Court Of The University Of Aberdeen | Isolation of therapeutic target specific VNAR domains to ICOSL |
-
2014
- 2014-04-23 US US14/785,975 patent/US10472410B2/en active Active
- 2014-04-23 RU RU2015146418A patent/RU2015146418A/ru not_active Application Discontinuation
- 2014-04-23 EP EP14718999.7A patent/EP2989203B1/en active Active
- 2014-04-23 DK DK14718999.7T patent/DK2989203T3/da active
- 2014-04-23 KR KR1020157033307A patent/KR20160010466A/ko not_active Withdrawn
- 2014-04-23 CN CN201480035865.XA patent/CN105492610B/zh active Active
- 2014-04-23 KR KR1020157033430A patent/KR102320189B1/ko active Active
- 2014-04-23 EP EP14720559.5A patent/EP2989204B1/en active Active
- 2014-04-23 CA CA2909921A patent/CA2909921C/en active Active
- 2014-04-23 BR BR112015026729A patent/BR112015026729A2/pt not_active Application Discontinuation
- 2014-04-23 EP EP19208141.2A patent/EP3683312B1/en active Active
- 2014-04-23 WO PCT/EP2014/058251 patent/WO2014173959A2/en not_active Ceased
- 2014-04-23 CA CA2909923A patent/CA2909923A1/en not_active Abandoned
- 2014-04-23 AU AU2014257549A patent/AU2014257549B2/en active Active
- 2014-04-23 JP JP2016509455A patent/JP6591964B2/ja active Active
- 2014-04-23 CN CN201480035842.9A patent/CN105531370A/zh active Pending
- 2014-04-23 AU AU2014257565A patent/AU2014257565A1/en not_active Abandoned
- 2014-04-23 BR BR112015026716A patent/BR112015026716A2/pt not_active IP Right Cessation
- 2014-04-23 US US14/786,074 patent/US10202438B2/en active Active
- 2014-04-23 RU RU2015146419A patent/RU2015146419A/ru not_active Application Discontinuation
- 2014-04-23 WO PCT/EP2014/058276 patent/WO2014173975A1/en not_active Ceased
- 2014-04-23 JP JP2016509450A patent/JP6616284B2/ja active Active
-
2019
- 2019-02-11 US US16/271,959 patent/US11459377B2/en active Active
- 2019-07-18 AU AU2019206064A patent/AU2019206064A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015146418A (ru) | Библиотека синтетических специфически связывающих молекул | |
| Arbabi-Ghahroudi | Camelid single-domain antibodies: promises and challenges as lifesaving treatments | |
| JP2016524463A5 (enExample) | ||
| JP4294596B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| CN106604932B (zh) | 人白细胞介素-2的免疫刺激单克隆抗体 | |
| JP2022531113A (ja) | 組換えポリクローナルタンパク質およびその使用方法 | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| JP2016524592A5 (enExample) | ||
| Hanke et al. | Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies | |
| JP2020505001A (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| CN107667115A (zh) | 针对埃博拉病毒糖蛋白的人抗体 | |
| JP2018537421A5 (enExample) | ||
| JP2019503990A (ja) | 改良された血清アルブミン結合剤 | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| JP2015518479A5 (enExample) | ||
| BR112021003410A2 (pt) | anticorpos de domínio único anti-bcma, grupo de genes dos ditos anticorpos, polipeptídeo, vetor de expressão, célula hospedeira, receptor de antígeno quimérico, célula t modificada pelo mesmo, composição farmacêutica e usos dos ditos anticorpos | |
| KR20210143804A (ko) | 혈액암 및 고형 종양암의 치료를 위한 키메라 항원 수용체 변형된 t 세포 (car-t) | |
| Silva-Pilipich et al. | A small virus to deliver small antibodies: new targeted therapies based on AAV delivery of nanobodies | |
| WO2021012195A1 (zh) | 可结合sftsv的纳米抗体及其应用 | |
| AU2015221388A1 (en) | Methods of modulating an immune response | |
| JP2021518168A (ja) | 拮抗的抗原結合タンパク質 | |
| KR20180020142A (ko) | Iii형 분비계 표적화 분자 | |
| RU2018121413A (ru) | Антитело ANTI-PCSK9 и его применение | |
| KR102654105B1 (ko) | 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180822 |